Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Neoadjuvant Nivolumab and chemotherapy in stage I-II triple negative breast cancer. Ended

2024-512625-86-00 Early stage triple negative breast cancer 4 2022-01-27
Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended

2024-514570-43-00 Renal cell carcinoma 5 2022-01-24
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL Ended

2024-511489-35-00 Relapsed/refractory Non Hodgkin Lymphoma 3 2022-01-24
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Ended

2023-506922-35-00 Locally Advanced or Metastatic Solid Tumors with EGFR a 1 2022-01-24
Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended

2024-514907-32-00 non-metastatic soft tissue sarcoma 3 2022-01-21
A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination Wi… Ended

2023-509996-18-00 Locally advanced and metastatic solid tumor including n 1 2022-01-18
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended

2024-513707-14-00 Only patients with oncologic locally advanced or metast 5 2022-01-14
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Muscle-Invasive Urothelial Carcinoma of the Bladder 4 2022-01-09
A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an… Ended

2024-515071-35-00 Somatostatin Receptor Positive Neuroendocrine Tumours ( 6 2022-01-06
A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelody… Ended

2023-506117-22-00 Acute Myeloid Leukemia and Myelodysplastic Syndromes 3 2022-01-05
Sotorasib (AMG 510) in Subjects with NSCLC with KRASG12C Mutation in Need of First-Line Treatment Ended

2024-511189-36-00 Non-small cell lung cancer (NSCLC) 4 2021-12-23
DAVINCY trial: optimal Duration of (fos)Aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind p… Ended

2024-517846-32-00 Delayed chemotherapy induced nausea and vomiting (CINV) 5 2021-12-21
Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1) Ended

2024-514168-15-00 N+M0 prostate cancer 3 2021-12-17
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in… Ended

2023-503406-36-00 Male and female participants at least 18 years of age w 4 2021-12-13
GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended

2024-510722-10-00 Malignant Solid Tumors 7 2021-12-13
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Participants with completely resected Stage III or Stag 5 2021-12-03
PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer Ended

2024-515850-26-00 patients with newly discovered brain metastases (non-sm 4 2021-12-03
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended

2024-512052-38-00 Advanced triple negative breast cancer 9 2021-12-02
Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended

2024-510762-16-00 Metastatic head and neck squamous cell carcinoma (HNSCC 4 2021-11-30
Clinical trial of MK-4280A for colorectal cancer that has spread after previous treatment Ended

2024-511043-25-00 Colorectal Cancer 5 2021-11-30
LAVA1207-001/LAVA1207-002 A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immun… Ended

2024-515821-27-00 Prostate Cancer 9 2021-11-30
FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage Ended

2024-512314-17-00 Aneurysmal Subarachnoid Hemorrhage (SAH) 5 2021-11-24
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected… Ended

2023-509688-25-00 Advanced solid tumors 3 2021-11-23
A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended

2024-511999-32-00 Advanced/Metastatic EGFR-expressing Cancers 9 2021-11-19